A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes
Abstract Background Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to β-interferon. It acts against CD52, leading primarily to lymphopenia. Recent data have shown that mild neutropenia is observed...
Main Authors: | A. G. Vakrakou, D. Tzanetakos, S. Valsami, E. Grigoriou, K. Psarra, J. Tzartos, M. Anagnostouli, E. Andreadou, M. E. Evangelopoulos, G. Koutsis, C. Chrysovitsanou, E. Gialafos, A. Dimitrakopoulos, L. Stefanis, C. Kilidireas |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-10-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12883-018-1183-4 |
Similar Items
-
Inclusion Body Myositis Treated with Alemtuzumab
by: Juliana Sá, et al.
Published: (2019-12-01) -
Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia
by: Jan J. Meeuse, et al.
Published: (2007-12-01) -
Meccanismo d’azione dei farmaci più recenti, Teriflunomide e Alemtuzumab e implicazioni terapeutiche
by: Francesco Patti
Published: (2015-11-01) -
Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01) -
Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)